((自动化翻译由路透提供，请见免责声明 ))
12月23日 - ** 药物开发商Rapt Therapeutics的 股价盘前上涨59.9%至1.32美元
** Rapt Therapeutics公司与中国上海杰敏康药业有限公司就一种实验性过敏治疗药物达成许可协议
** Jemincare获得 3500 万美元的预付许可费和高达 6.725 亿美元的额外里程碑 付款
** RPT904是 诺华 Xolair的替代品，该药被批准用于治疗包括哮喘在内的多种过敏性疾病。
** 作为交易的一部分，RAPT公司获得了除中国大陆、香港、澳门和台湾以外的全球范围内开发和商业化 RPT904 的权利。
** 该公司表示，RAPT 计划首先开发 RPT904，用于治疗 食物过敏。
** 另外，杰敏康正在中国 进行治疗 哮喘和慢性自发性荨麻疹（一种皮肤病）的中期试验 。
** 截至上次收盘，该股今年累计下跌 96.7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.